CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 54 enrolled
Drug / intervention
Restylane SubQ +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01431755
NCT01431755N/ACompleted

A Randomised, Subject-blinded Study of Treatment Preference During Cheek Contouring Comparing Restylane® SubQ With and Without the Addition of Lidocaine Hydrochloride 0.3%

Galderma R&D·interventional·Posted Sep 12, 2011·Updated Sep 22, 2022

In Brief

A clinical study evaluating Restylane SubQ and Restylane SubQ Lidocaine for Facial Tissue Augmentation. Completed, enrolled 54 participants across 3 sites.

Detailed Summary

The objectives of this study are to evaluate the pain-relieving effect and safety of adding lidocaine hydrochloride to Restylane SubQ and to evaluate the esthetic improvement obtained. The study products will be administered in the cheek.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSweden
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 12, 2011
Enrollment StartSep 1, 2011
Primary CompletionOct 1, 2011
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 14.8 years ago

Interventions

Restylane SubQdevice

Treatment with up to 2 ml of the product

Restylane SubQ Lidocainedevice

Treatment with up to 2 ml of the product